16 October 2018
Highlights in Medicinal Chemistry III
Organised by:
SCI's Fine Chemicals Group
London, UK
Share this event
Synopsis
This meeting aims to showcase vignettes of modern medicinal chemistry to bring new thinking to the subject, challenge perceptions and encourage scientific interaction between researchers. The short presentation format of the meeting also aims to provide a focussed forum to promote examples of medicinal chemistry excellence.Attendees
This meeting is targeted at academic and industrial scientists engaged in all aspects of the drug discovery process and those interested in broadening their knowledge at the forefront of medicinal chemistry.Programme
| 09.20 | Registration and refreshments | |
| 09.50 | Opening remarks | |
| 09.55 | Drug discovery beyond the rule of 5 - outer limits of oral absorption and insight into design at the extremes Prof Jan Kihlberg, University of Uppsala, Sweden |
|
| 10.35 | Discovery of potent cyclophilin inhibitors based on structural simplification of Sanglifehrin A Dr Vicky Steadman, Eurofins - Selcia, UK |
|
| 11.00 | The development of an intracellular degradation probe for pirin protein Dr Nicola Chessum, Institute of Cancer Research, UK |
|
| 11.25 | Refreshment break | |
| 11.45 | Potency and patents, new arenas for matched molecular pair analysis Dr Edward Griffen, MedChemica Ltd, UK |
|
| 12.10 | Predictive computational approaches to guide the covalent targeting of cysteine residues in drug discovery Dr Richard Ward, AstraZeneca, UK |
|
| 12.35 | Strategies for the design of brain penetrant kinase inhibitors Dr Sarah Skerratt, Vertex Pharmaceuticals, UK |
|
| 13.00 | Lunch and exhibition | |
| 14.00 | Structural insights into modulation of the orexin receptors
Dr John Christopher, Heptares, UK |
|
| 14.25 | From fragment to candidate for a protein-protein interaction target Dr Rhian Holvey, Astex Pharmaceuticals, UK | |
| 14.50 | Chemical strategies to achieve broad-spectrum antibacterial activity
Dr Alastair Parkes, Evotec Ltd, UK |
|
| 15.30 | Refreshment break | |
| 15.50 | Discovery of a clinical candidate for the inhibition of DGAT2 Dr Rosario Gonzalez, Eli Lilly, Spain |
|
| 16.15 | Discovery and application of 3-oxabicyclo[4.1.0]heptane, a non-nitrogen containing morpholine isostere, through predictive Quantum Mechanical modelling Dr Heather Hobbs, GlaxoSmithKline, UK |
|
| 16.40 | Synthesis-driven chemical biology and medicinal chemistry
Prof Matthew Gaunt, University of Cambridge, UK |
|
| 17.20 | Closing remarks | |
| 17.25 | Networking and refreshments |
Venue and Contact
SCI
14/15 Belgrave Square
London
SW1X 8PS
Conference Team
Tel: +44 (0)20 7598 1561
Email: conferences@soci.org
Fees
Early bird fees before Monday 3 September 2018
| One-Day Fee | Two-Day Fee* | ||
| SCI Member | £100 | SCI Member | £175 |
| SCI Student Member | £35 | SCI Student Member | £60 |
| Non-Member | £130 | Non-Member | £235 |
*The Two-Day Fee includes attendance at 'Designing Safer Medicines III' on Monday 15 October and 'Highlights in Medicinal Chemistry III' on Tuesday 16 October
Standard fees after Monday 3 September 2018
| One-Day Fee | Two-Day Fee* | ||
| SCI Member | £115 | SCI Member | £205 |
| SCI Student Member | £40 | SCI Student Member | £70 |
| Non-Member | £150 | Non-Member | £270 |
Become an SCI Member and save on this and future events
See Membership OptionsSign up as an Event Member to join this event. SCI Full or Student Members receive discounts on event registrations
Booking Process
For bookings terms and conditions click here.CPD Info
Exhibitors
Sponsors
Organising Committee
- Sarah Major, SCI / Evotec
- Nigel Swain, SCI / Heptares
- Al Dossetter, SCI / Mechemica Ltd
- Joanne Pinder SCI / Vertex Pharmaceuticals
- Iain Simpson SCI / AstraZeneca